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Abstract
Background: Wearable long-duration low-intensity ultrasound is an emerging non-invasive and non-narcotic therapy
for the daily treatment of musculoskeletal pain. The aim of this randomized, double-blind, placebo-controlled study
was to examine whether long-duration low-intensity ultrasound was effective in treating pain and improving function
in patients with knee osteoarthritis.
Methods: Ninety patients with moderate to severe knee pain and radiographically confirmed knee osteoarthritis
(Kellgren-Lawrence grade I/II) were randomized for treatment with active (n = 55) or placebo (n = 35) devices applied
daily to the treated knee. Investigators and subjects were blinded to treatment groups. Ultrasound (3 MHz, 0.132 W/cm2,
1.3 W) was applied with a wearable device for 4 h daily for 6 weeks, delivering 18,720 J per treatment. The primary
outcome was change in pain intensity (numeric rating scale) assessed prior to intervention (baseline) and after 6 weeks.
Secondary outcomes of functional change were measured at baseline and after 6 weeks using the Western Ontario
McMaster Osteoarthritis Questionnaire (n= 84), along with range of motion (flexion, extension) and isometric muscle
strength (flexion, extension and rotation) tests on the injured knee in a small pilot subset (n = 17).
Results: The study had a 93% retention rate, and there were no significant differences between the groups regarding
demographic variables or baseline outcome measures. Patients treated with active therapy observed a significant mean
NRS pain reduction over the 6-week study of 1.96 points for active (p < 0.0001), compared with a 0.85 points reduction for
placebo (p = 0.13). The functional score was also significantly improved by 505 points for the active group over the
311-point improvement for placebo group compared to baseline (p = 0.02). In the pilot subset evaluated, rotational
strength increased from baseline to 6 weeks (3.2 N, p = 0.03); however, no other measures were significant.
Conclusions: Long-duration low-intensity ultrasound significantly reduced pain and improved joint function in
patients with moderate to severe osteoarthritis knee pain. The clinical findings suggest that ultrasound may be used as
a conservative non-pharmaceutical and non-invasive treatment option for patients with knee osteoarthritis. Additional
research is warranted on non-weight bearing joints of the musculoskeletal system as well as extended treatment time
frames and follow-up.
Trial registration: NCT02083861, registered 11 March 2014, https://clinicaltrials.gov/ct2/show/results/NCT02083861
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Background
Osteoarthritis (OA) is a serious and debilitating health
problem affecting more than 27 million Americans and
is a common work-related injury simulated by repetitive
stresses [1]. Arthritis impacts nearly one in three adults
between the ages of 45 and 65 and half of all adults over
65, with consistent effect across multiple races and
ethnicities [2]. The number of OA patients is projected
to increase as the population skews older and obesity
rates rise. The disease is characterized by degeneration
of articular cartilage and joint inflammation together
with chronic pain, stiffness, swelling, and limited mobi-
lity. Chronic pain from OA significantly affects patients’
quality of life, work productivity, and is associated with
comorbidities such as depression, anxiety, and sleep dis-
turbance [1]. The disease can develop from trauma,
overuse, and genetic factors in any joint of the body, but
it is most commonly found in the knee, hip, spine,
shoulders, and hands. Osteoarthritis exacts an enormous
financial toll on the healthcare system, as the second
most expensive condition for US hospitals, with aggre-
gate costs of $14.8 billion in 2011 alone [3].
The most frequent treatment for OA is prescription
painkillers and anti-inflammatory medications [4].
Serious health risks are associated with these medica-
tions, including addiction and increased risk for gastro-
intestinal, renal, and cardiovascular problems. Topical
non-steroidal anti-inflammatory drugs (NSAIDs) have
partially addressed this issue, but many people with OA
do not get sufficient pain relief with NSAIDs alone [5,
6]. Intra-articular hyaluronic-acid injections provide an
alternative but are not a consistent approach to pain
relief and can be painful to administer to patients [7].
Although non-pharmaceutical therapies such as physical
therapy, exercise, massage, therapeutic ultrasound, water
aerobics, and others exist to treat the symptoms of OA,
many patients lack the ability or resources to access
these therapies leading to worse knee OA pain and pro-
gressive disability [8].
Ultrasound treatment has been utilized in the medical
setting with minimal safety risks for the symptomatic
management of OA pain for many years; however, the
clinical efficacy of office-based ultrasound remains
controversial. In 2010, a Cochrane review determined
that ultrasound may provide clinical value for knee OA
patients by reducing pain and improving function and
quality of life and that larger-scale clinical trials were
justified [9]. More recently, new clinical trials on OA
and rheumatoid arthritis, along with multiple meta-ana-
lyses of the literature, have found statistical support indi-
cating that consistent ultrasound treatment of OA
symptoms is more effective than placebo controls [10].
Specifically, for knee OA pain, ten randomized
controlled trials (645 patients) treated with ultrasound
showed a positive effect over placebo on knee pain and a
reduction in the Western Ontario and McMaster
Universities Arthritis Index (WOMAC) score [11].
Current existing evidence suggests ultrasound adminis-
tered daily is effective for OA symptomatic management
[11]. Unfortunately, daily ultrasound treatment in the
clinical setting is unrealistic for many patients and
medical professionals.
The aim of this randomized double-blinded placebo-
controlled study was to determine whether a wearable
home-use long-duration daily low-intensity ultrasound
therapy is an effective treatment option for patients with
knee osteoarthritis symptoms. Our study utilized sus-
tained acoustic medicine (SAM), a United States Food
and Drug Administration approved (2013) prescription
use wearable multi-hour ultrasound device to investigate
the efficacy of long duration ultrasound in treating
osteoarthritic pain and disability. Validated measures of
OA pain, stiffness, function, and strength were used to
determine effectiveness.
Methods
This prospective randomized, double-blinded, placebo-con-
trolled, study was conducted in the USA and registered
with ClinicalTrials.gov identifier NCT02083861. Patients
meeting inclusion criteria, and who successfully completed
2 weeks of baseline pain measures were randomized 3:2 for
a 6-week treatment with active (n = 55) or placebo (n = 35)
SAM device. Patients subsequently self-applied the respec-
tive treatment 4 h per day for 6 weeks to the lateral and
medial arthritic knee. Measurements of pain were recorded
in a daily patient diary, while functional measurements
were completed during clinic visits. The study was
approved by the institutional review board of Schulman
Associates, and all patients provided informed consent to
participate. The procedures followed were in accordance
with the ethical standards of the responsible committee on
human experimentation and with the Helsinki Declaration
of 1975, as revised in 2000.
The study was conducted in the Central New York
region of the USA between March 2014 and January
2015. Patient enrollment was accomplished through a
referral from Cayuga Medical Center, the community
hospital, to Medical Pain Consultants LLC, the affiliated
ambulatory care practice in Dryden, NY. The practice
served as the setting for enrollment, training on the use
of the device, 2-week visits of the patients with research
staff, and pre/post functional measurements. The
patient’s home/work setting served as the setting at
which the device was self-administered and where pain
measurements were recorded.
Included patients were 35 to 80 years of age, reported
moderate to severe knee OA pain negatively affecting their
life, were radiographically-confirmed mild to moderate
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knee osteoarthritis (Kellgren-Lawrence (KL) grade I/II
[12]) in one or both knees based on fixed-flexion x-ray
radiological findings for osteophytes or joint space nar-
rowing in any compartment in the previous 12 months,
and reported average baseline pain score between 3 and 7
on the numeric rating scale (0–10 NRS) the week prece-
ding enrollment. In cases of bilateral knee OA, the more
painful knee was selected for treatment; if equal pain, a
flip of a coin was used to select the knee for treatment.
Exclusion criteria included having presence of severe
knee OA (KL grade III); having had a knee replacement,
surgical intervention, or hyaluronic acid injection in the
affected knee in the previous 6 months; being a
non-ambulatory patient; being unable to self-apply the
device to their knee; having current treatment with
corticosteroids; or having had osteoarthritis develop
secondary to a metabolic disorder.
Baseline measurements and randomization
Pain scores were recorded three times each day in a paper
diary during the 2-week baseline period (weeks 1–2).
Upon completion of baseline data, patients were asked to
meet with clinical site staff to review data entry into the
diary. WOMAC scores were obtained at the end of the
baseline period for all subjects continuing to the treatment
protocol (n = 90). A small pilot cohort was assessed for
clinic-administered range of motion and muscle strength
at the end of the baseline period (n = 17). Then, patients
were randomized using a computer-generated random
number list into either the active group, in which they re-
ceived an active wearable device, or the placebo group, in
which they received a device that functioned and appeared
like the active device but did not emit ultrasound energy
(deactivated transducers provided by the manufacturer).
Treatment arms were balanced by age, sex, and BMI.
Treatment allocation was concealed from the clinic and
research staff enrolling patients and performing data entry
for analysis. Study patients, the investigator, research assis-
tants, and study staff were blinded to the intervention.
Intervention protocol
The long-duration low-intensity ultrasound treatment
phase lasted 6 weeks (weeks 3–8). Patients were permitted
to continue use of pain medications as long as those medi-
cations were maintained at a stable dose throughout the
trial. Co-interventions were not assessed in this study.
Ultrasound was self-administered in the home-setting
with a wearable US Food and Drug Administration (FDA)
approved (2013) class II prescription medical device
SAM® Sport (ZetrOZ Systems, LLC, Trumbull, CT). The
device was self-administered 4 h per day, 7 days per week
for 6 weeks. The device operates at 3 MHz in continuous
wave mode and delivers 1.3 W output power divided
evenly across two transducers. The average ultrasonic
intensity from each transducer is 132 mW/cm2 and the
device delivers a total acoustic dose of 18,720 J of energy
over the 4-h treatment period. The device is attached to
the body with a disposable adhesive patch which comes
pre-filled with ultrasonic coupling gel. At the clinic,
patients were shown how to apply the transducers to the
medial and lateral sides of the arthritic knee and set the
medical devices treatment timer for 4 h of continuous
ultrasound (Fig. 1). Patients were instructed to wear the
device during normal daily activity and apply/remove the
device when convenient with their daily schedule. Each
patient randomized for treatment received one recharge-
able device and three 40-packs of adhesive patches (120
individual units).
Primary outcome
The primary outcome was weekly change in pain inten-
sity relative to baseline through 6 weeks of therapy, as
measured on the numeric rating scale (NRS) (0 = no
pain, 10 = extreme pain). The NRS pain scale has been
validated for consistency and reliability to assess pain
associated with a variety of conditions, including OA
[13]. Patients recorded their pain 4 h after applying the
device during daily treatment.
Secondary outcomes
Secondary outcome measures assessed were change in
WOMAC score for pain stiffness and function, range of
Fig. 1 Wearable daily use ultrasound device. The wearable daily
home-use long-duration low-intensity ultrasound device (SAM® Sport,
ZetrOZ Systems LLC, Trumbull, CT) applied to the medial and lateral
articulation points of the knee for the treatment of knee OA. The
device is a prescription use only in the USA and has preconfigured
ultrasound parameters of 3 MHz frequency and 1.3 W of energy for
daily applied 4-h treatment
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motion, and muscle strength assessed at baseline and
the end of the study. Range of motion and strength
measurements were acquired by trained clinic staff on a
small pilot cohort (n = 17) of sequentially enrolled
patients using computerized dual inclinometry range of
motion and muscle tester equipment (JTECH Medical,
Midvale, UT). To assess range of motion, one inclino-
meter was positioned on the quadricep muscle at mid
femur and the other at mid-tibia. Patients were asked to
lay flat on their back and lift their leg and flex at the
knee to measure flexion. Patients were then asked to sit
at the edge of the table and extend their leg to measure
extension. To assess muscle strength, a manual muscle
tester was used. Patients were asked to sit at the edge of
the table with their knee at approximately 90 degrees.
The manual muscle tester was positioned and held at
anterior mid tibia while patients were asked to extend
their leg to measure extension strength. To measure
flexion strength, the muscle tester was held at anterior
mid-tibia and the patient was asked to flex at the knee.
Each range of motion and muscle strength test was re-
peated three times and the average was recorded.
Follow-up
Once enrolled in the study, patients completed in-office
visits on week 1 (patient enrollment and informed
consent), week 3 (treatment randomization), week 5 (pa-
tient follow-up), week 7 (patient follow-up), and week 8
(study completion). During follow-up visits, the research
staff reviewed the patient’s daily pain diary, addressed
any questions the patient had about using the device or
being involved in the study, and monitored for any ad-
verse events (i.e., a serious unanticipated injury or death)
or reactions (e.g., skin sensitivity, redness or burn) from
the device.
Statistical analysis
Chi-squared proportional assessment was used to assess
gender demographics between groups, and t tests were
used to analyze other demographic and outcome data.
Data analysis was conducted in the R software environ-
ment for statistical computing (The R Foundation for Sta-
tistical Computing, Vienna, Austria). Data are expressed
as means ± SDs (standard deviations). Statistical signifi-
cance was achieved with p values less than 0.05.
Results
Enrollment and demographics of patient population
A total of 114 patients were screened; 93 patients en-
rolled, and 90 patients were randomized into active or
placebo groups (Fig. 2). Ten patients discontinued the
study before it was completed: two indicated the study
Fig. 2 Study flow chart. Flow chart describing the progress of patients through the clinical trial on knee OA
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was too much work; two discontinued because of skin
irritation (from the device); two were lost to follow-up;
one discontinued for an unrelated medical issue; and
three were lost from damaged medical equipment that
was unable to be replaced. There were eight confirmed
protocol violations, one in which the patient incorrectly
applied the device on the unassigned knee that had a
prior knee replacement, and seven patients who applied
the device to both the assigned and unassigned knee. Of
patients who completed the 2-week baseline assessment
(n = 93), 90 were randomized into two ultrasound inter-
vention groups (n = 55 active and n = 35 placebo). A
total of n = 51 active and n = 33 placebo completed
6 weeks of therapy resulting in a 93% retention rate for
the intervention.
The patient demographics for treatment intervention
are shown in Table 1. After dropouts, treatment arms
contained subjects with mean age 53.6 years active and
51.1 years placebo, gender 23/28 male/female active and
16/17 male/female placebo, and body mass index
34.9-BMI active and 34.5-BMI placebo. On average, pa-
tients had moderate pain at baseline 5.53-NRS active,
5.26-NRS placebo. No significant differences or trends
were found between baseline pain and BMI for the
groups (active versus placebo), or by gender. Approxi-
mately 88% (74 patients) of the study population was
non-Hispanic Caucasian and 12% (10 patients)
non-Hispanic African American. Enrolled patients were
taking a median of four prescriptions during the course
of the study. The most common pain medications were
prescription NSAIDs and oxycodone, either in short-act-
ing form (10 mg median dose) or sustained release
(20 mg median dose). Cointervention results were not
investigated in this study.
Primary outcome measure of knee OA pain
There was a significant reduction of pain from baseline
to the end of 6 weeks of therapy favoring activate
low-intensity ultrasound treatment. Pain was reduced by
1.96 points for active, which was significant compared to
0.85-points reduction for placebo (1.11-point difference,
p = 0.04) SAM device (Table 2). The active group chan-
ged significantly from baseline placebo group did not
change significantly from baseline (p = 0.13).
Secondary outcome measures of knee functional
improvement
The WOMAC score measuring pain, stiffness, and func-
tion was significantly improved for active SAM by 505
points (p < 0.0001) and 311 points for placebo (p = 0.0002)
after 6 weeks of intervention (Table 3). The improvement
in the active group was significantly greater than the
improvement of the placebo group (193-point difference,
p = 0.02). For WOMAC pain, the change of 107 points in
the active group was significantly greater than that in the
placebo group of 60.8 points (p = 0.02). For WOMAC
stiffness, the change in the active group of 45 points was
again significantly greater than that in the placebo group
of 17 points (p = 0.002). For WOMAC function, the change
in the active group of 352 points was significantly greater
than the 220 points of the placebo group (p = 0.03).
JTECH range of motion and strength measurements
of the treated leg for active and placebo SAM are shown
in Table 3. In total, five unique measurements where
completed at baseline and after 6 weeks of intervention
for n = 8 active and n = 9 placebo patients. These in-
cluded flexion and extension along with muscle strength
during neutral flexion, flexion-rotation, and extension.
Independently, the range of motion and strength
measurements were not significantly different, with the ex-
ception of muscle strength in flexion-rotation, with p values
all above 0.1 for active versus placebo and comparing base-
line to 6 weeks post-treatment. Strength in flexion-rotation
increased 3.21 N in the active group after 6 weeks of treat-
ment compared to baseline (p = 0.03).
Table 1 Patient demographics of knee OA clinical trial
Patient demographic data
Variable Active ultrasound Placebo ultrasound p
n 51 31
Sex (M/F) 23/28 16/17 0.115
Age, years 53.6 ± 8.9 51 ± 9.0 0.198
BMI 34.9 ± 8.85 34.5 ± 8.3 0.834
Table 2 Pain on the NRS (0–10) scale reported daily in the
patient diary after completion of 4-h ultrasound treatment.
Mean ± SD
Primary outcome NRS data
Week Active Placebo Mean difference
95% CI
p
Baseline 5.53 (± 2.37) 5.26 (± 2.34) 0.27 (− 0.74 to 1.28) 0.59
2 weeks 3.61 (± 2.53) 4.48 (± 2.27) − 0.87 (− 1.91 to 0.17) 0.10
4 weeks 3.29 (± 2.58) 4.26 (± 2.42) − 0.97 (− 2.08 to 0.14) 0.08
6 weeks 3.57 (± 2.58) 4.41 (± 2.25) − 0.84 (− 1.90 to 0.22) 0.11
NRS mean change from baseline 95% CI
2 weeks − 1.92 ± 2.39 − 0.78 ± 2.37 − 1.14
(− 2.18 to − 0.10)
0.03
− 2.86 to − 0.98 − 1.89 to 0.32
p < 0.001 p = 0.16
4 weeks − 2.24 ± 2.47 − 1.00 ± 2.34 − 1.24
(− 2.31 to − 0.17)
0.02
− 3.20 to 1.28 − 2.15 to 0.15
p < 0.001 p = 0.09
6 weeks − 1.96 ± 2.50 − 0.85 ± 2.41 − 1.11
(− 2.20 to − 0.02
0.04
− 2.92 to 1.00 − 1.96 to 0.26
p < 0.001 p = 0.13
Draper et al. Journal of Orthopaedic Surgery and Research  (2018) 13:257 Page 5 of 9
Table 3 Secondary outcome measures, Western Ontario McMaster Osteoarthritis Questionnaire (WOMAC), and range of motion
(ROM) and muscle strength measurements
Secondary outcome measurements
Variable Baseline Endpoint Endpoint group difference
Active Placebo p Active Placebo Mean 95% CI p
WOMAC Assessment
n 55 35 51 31
WOMAC pain 292 ± 89.1 276.5 ± 77.9 0.40 185 ± 103.2 215.7 ± 81.5 − 30.4 0.150
− 72.4 to 11.6
WOMAC pain mean change from baseline 95%CI − 107.3 ± 97.5 − 60.8 ± 80.95 − 46.5
− 85.6 to − 7.4
0.020
− 147.6 to − 66.8 − 100.3 to − 21.2
p < 0.0001 p = 0.003
WOMAC stiffness 125 ± 35.8 123.5 ± 42.7 0.85 80.2 ± 41.1 106.4 ± 31.1 − 26.2
− 43.1 to 9.3
0.003
WOMAC stiffness mean change from baseline 95%CI − 45 ± 39.0 − 17.1 ± 38.5 − 27.9
− 45.1 to − 10.7
0.002
− 61.1 to − 28.9 − 36.0 to 1.9
p < 0.0001 p = 0.080
WOMAC function 975 ± 272.2 974 ± 218.3 0.99 622.9 ± 336.7 754.8 ± 241.4 − 131.9
− 263.2 to 0.7
0.049
WOMAC function mean change from baseline 95%CI − 352.3 ± 309.6 − 220.1 ± 233.6 − 132.2
− 250.5 to − 13.9
0.029
− 480.7 to − 224 − 334.3 to − 105.9
p < 0.0001 p = 0.0002
WOMAC total 1393 ± 377 1375 ± 299.4 0.81 888.4 ± 471 1063.7 ± 351.7 − 175.3
− 362.1 to 11.5
0.066
WOMAC total mean change from baseline 95%CI − 504.6 ± 431.5 − 311.2 ± 331.33 −193.4
− 359.6 to − 27.2
0.023
− 683.4 to − 325.7 − 473.4 to − 148.9
p < 0.0001 p = 0.0002
ROM and strength assessments
n 9 8 9 8
ROM flexion (°) 41.5 ± 35.0 36.8 ± 28.5 0.76 35.1 ± 27.9 34.6 ± 25.1 0.570
− 27.1 to 28.2
0.97
ROM flexion mean change from baseline 95% CI − 6.38 ± 33.6 − 2.22 ± 38.2 − 4.16
− 6.38 to − 2.22
0.79
− 40.5 to 27.8 − 29.1 to 24.6
p = 0.69 p = 0.86
ROM extension (°) 39.5 ± 35.9 37.1 ± 29.5 0.88 21.8 ± 28.0 31.6 ± 25.7 −9.81
−37.8 to 18.2
0.46
ROM extension mean change from baseline 95% CI − 17.75 ± 34.1 − 5.56 ± 29.34 − 12.19
− 46.0 to 21.7
0.45
− 52.5 to 17.0 − 33.2 to 22.1
p = 0.29 p = 0.68
Strength flexion (N) 8.05 ± 3.64 10.4 ± 6.31 0.37 9.39 ± 2.92 11.4 ± 2.84 − 2.03
− 5.03 to 0.960
0.17
Strength flexion mean change from baseline 95% CI 1.34 ± 3.50 1.01 ± 5.19 0.33
− 5.26 to 5.92
0.90
− 2.22 to 4.89 − 4.06 to 6.08
p = 0.43 p = 0.67
Strength rotation (N) 6.06 ± 2.22 9.91 ± 5.52 0.086 9.28 ± 3.10 10.6 ± 3.09 − 1.31
− 4.52 to 1.90
0.40
Strength rotation mean change from baseline 95% CI 3.21 ± 2.86 0.68 ± 4.74 2.53
− 2.20 to 7.25
0.25
0.294 to 6.06 − 3.89 to 5.25
p = 0.03 p = 0.75
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Discussion
The wearable SAM device can be successfully adminis-
tered for use in the home setting under the monitoring
of a healthcare professional familiar with low-intensity
ultrasound devices. This non-pharmacological therapy
shows high patient compliance and significantly
improves symptomatic management of patients with KL
grade I/II knee OA. In this study, 84 of 90 patients com-
pleted the SAM intervention phase (93% retention). The
six patients who did not complete the study was a result
of damage to the device (3), skin irritation (2), and no
follow-up (1). Active SAM significantly reduced knee
pain on average by 1.96 points after the 6-week interven-
tion period (p < 0.001). Additionally, pain, stiffness, and
function (WOMAC) improved significantly for patients
with KL grade I/II knee OA treated with active SAM
over the placebo group (p = 0.02, p = 0.002, p = 0.029
respectively).
These results are consistent with ultrasound literature
for the symptomatic treatment of OA [14]. In a rando-
mized, placebo-controlled study of daily ultrasound to
treat hip osteoarthritis for 2 weeks, a significant
1.2-point difference on the visual analogy scale was
found [15]. Another placebo-controlled study of ultra-
sound on knee osteoarthritis found similar results with
a 2.8-point decrease in pain on the NRS after ten treat-
ment sessions, and a significant 1.7-point difference in
pain score between active and placebo ultrasound [16].
These and additional clinical findings are similar to the
results of this study supporting ultrasound treatment
for OA when applied five or more times per week [17].
In this study, patients with knee OA had an average
BMI > 30 and were not asked to reduce or eliminate
their pain medications. The use of moderate levels of
prescription pain may have reduced the main effect of
the home intervention. Additionally, the patient popula-
tion was primarily Caucasian and the study was con-
ducted in a rural environment.
Limited patients were enrolled in the range of motion
and strength pilot studies. The active SAM group con-
sistently had larger improvement of individual outcome
measures; however, small group sizes potentially limited
the power of the statistical analysis. Future studies con-
ducted on range of motion and strength should include
larger sample sizes.
The use of low-intensity ultrasound in the home
setting appears to be an emerging treatment strategy
for the non-invasive management of knee OA. Using
a double-blind RCT design, the wearable SAM de-
vice was studied on a patient population which had
clinically meaningful benefit from this intervention.
Patients were able to use the device anytime during
the day.
Low-intensity long-duration ultrasound treatment of
arthritis pain is a novel, low-risk and non-invasive treat-
ment option. The SAM device used in this study costs
$4400 for 6 weeks of daily treatment, which is approxi-
mately half the cost of other low-intensity ultrasound
devices for daily patient treatment. The SAM device
used in this study permits the patient to set only the
treatment time (1 to 4 h), reducing the need for inten-
sive training of the patient. Furthermore, the wearable,
patient-applied, multi-hour treatment does not interfere
with the normal daily activity of the patient.
There are several similarities and differences worth
noting between the wearable SAM device and other
low-intensity ultrasound devices. The frequency and
power of operation are within the same clinically utilized
range of low-intensity ultrasound: between 1 to 3 MHz
and 0.1 to 1.3 W. However, the total energy delivered by
SAM was 18,720 J per 4-h treatment in this study, which
is 133 times greater than most low-intensity therapy
sessions which deliver 140 J per 20-min treatment.
Monitoring of SAM device use and adherence to the
study protocol was accomplished through in-office visits
every 2 weeks. Wearable SAM ultrasound was well
tolerated by the patients. In approximately 3528 unique
treatment sessions with the device, two skin irritations
were reported (less than 0.1%), and no significant safety
risks or adverse events found.
The SAM device is not the only prescription (1 to
3 MHz) wearable low-intensity ultrasound therapy device
Table 3 Secondary outcome measures, Western Ontario McMaster Osteoarthritis Questionnaire (WOMAC), and range of motion
(ROM) and muscle strength measurements (Continued)
Secondary outcome measurements
Variable Baseline Endpoint Endpoint group difference
Active Placebo p Active Placebo Mean 95% CI p
Strength extension (N) 7.79 ± 4.36 9.4 ± 5.29 0.51 9.70 ± 4.83 11.0 ± 2.81 − 1.30
− 5.59 to 2.99
0.50
Strength extension mean change from baseline 95% CI 1.91 ± 4.88 1.60 ± 4.49 0.31
− 4.78 to 5.40
0.90
− 3.03 to 6.85 − 2.74 to 5.94
p = 0.42 p = 0.43
p < 0.05 shown in italics
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available in the USA. Another device that provides 20 min
of daily low-intensity ultrasound at 1.5 MHZ (Exogen®,
Bioventus LLC, Durham, NC) was approved by the FDA in
1994. The use of wearable ultrasound may be considered as
a non-pharmaceutical and non-invasive home-use treatment
option for patients with moderate to severe osteoarthritis
pain. The intervention could be particularly meaningful for
arthritis patients who are not candidates or exploring
non-invasive alternative options to prescription NSAIDs
and narcotics, viscosupplements, or surgical procedures.
Future research on daily applied long-duration ultra-
sound shows promise to treat not only symptomology of
osteoarthritis but perhaps the disease progression itself
following joint injury or age-related degradation [18, 19].
The investigation into wearable low-intensity ultrasound
treatment for various disease progression states and phe-
notypes of OA would yield insight into particular subsets
of the OA population most likely to benefit from this
treatment. Laboratory research with animal models of
OA shows that ultrasound enhances expression of type
II collagen, along with improved chondrocyte cell
morphology and matrix integrity [20]. Whether or not
these findings could be replicated in humans remains
unknown. Ultrasound treatment in early-stage OA pro-
gression has significantly reduced the disease severity
[21], and ultrasound treatment may also resolve
arthritis-associated synovitis by mechanistically enhan-
cing the phagocytosis of macrophages [22]. These en-
couraging data on the potential slowing of disease
progression and the home-based ultrasound treatment
strategy warrant further study. Here, the intervention
period of 6 weeks was appropriate to capture meaningful
changes in self-reported pain using the wearable
low-intensity ultrasound device. Future research will
investigate the long-term outcomes of this treatment op-
tion. Such research could provide significant healthcare
benefit and perhaps change the way knee OA is
managed early in the patient care continuum.
Conclusions
Long-duration low-intensity ultrasound significantly re-
duced pain and improved joint function in patients with
moderate to severe osteoarthritis knee pain. WOMAC
scores were significantly reduced in the active ultra-
sound group including assessments for joint function.
ROM and strength data collection limited the statistical
power of findings here, and larger sample sizes may cor-
roborate with WOMAC functional assessments. The
clinical findings suggest that low-intensity ultrasound
may be used as a conservative treatment option for pa-
tients with knee osteoarthritis. Additional osteoarthritis
studies are necessary to determine the efficacy and com-
pliance of long duration ultrasound use in other joints
such as the spine.
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